Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals’ future looks uncertain after it revealed on 14 April that the US Food and Drug Administration indicated that it will need to see a confirmatory Phase III trial on top of data

Novo Nordisk’s blockbuster semaglutide franchise – Rybelsus and Ozempic for type 2 diabetes and Wegovy for obesity – was included in the Centers for Medicare and Medicaid Services (CMS) list of 15 dru

Who: Genentech/COUR Pharmaceuticals What: Roche subsidiary Genentech entered into a collaboration and licensing agreement with COUR Pharmaceuticals to develop and commercialize COUR’s tolerogenic n

Kalvista’s Momentum Dissipates When KalVista Pharmaceuticals, Inc. announced that its oral plasma kallikrein inhibitor, sebetralstat, met all the endpoints in the Phase III KONFIDENT study of 136 he